AC-1370の臨床的検討

武田 元; 岩永 守登; 和田 光一; 森本 隆夫; 荒川 正昭; 高頭 正長; 樋口 英嗣; 川島 士郎; 蒲沢 知子

doi:10.11250/chemotherapy1953.32.Supplement9_317

CLINICAL STUDIES ON AC-1370

HAJIMU TAKEDA, MORITO IWANAGA, KOUICHI WADA, TAKAO MORIMOTO, MASAAKI ARAKAWA, MASANAGA TAKATO, HIDETSUGU HIGUCHI, SHIRO KAWASHIMA, TOMOKO KABASAWA

Author information

HAJIMU TAKEDA
Second Department of Internal Medicine, Niigata University, School of Medicine
MORITO IWANAGA
Second Department of Internal Medicine, Niigata University, School of Medicine
KOUICHI WADA
Second Department of Internal Medicine, Niigata University, School of Medicine
TAKAO MORIMOTO
Second Department of Internal Medicine, Niigata University, School of Medicine
MASAAKI ARAKAWA
Second Department of Internal Medicine, Niigata University, School of Medicine
MASANAGA TAKATO
Department of Internal Medicine, Kouseiren Central Hospital
HIDETSUGU HIGUCHI
Department of Internal Medicine, Kouseiren Central Hospital
SHIRO KAWASHIMA
Department of Internal Medicine, Niigata Tsugawa Hospital
TOMOKO KABASAWA
Department of Internal Medicine, Kobari Hospital

JOURNAL FREE ACCESS

1984 Volume 32 Issue Supplement9 Pages 317-322

DOI https://doi.org/10.11250/chemotherapy1953.32.Supplement9_317

Details

Abstract

AC-1370 is a new parenteral cephalosporin antibiotic. The antibiotic was intravenously administrated to two patients with acute cystitis, each one patient with acute pyelonephritis, acute tonsillitis, chronic bronchitis, chronic bronchiolitis and fever of unknown origin, and eight patients with pneumonia. These patients received the drug for 3 to 38 days in doses of 1 to 4g/day. Twelve of these patients responded well in the therapy. Rash with and without fever were recognized as adversed effect in two patients.

Corresponding author

Register with J-STAGE for free!